Risk factors
Passage BIO (PASG) risk factors
Item 1A of every Passage BIO, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks3 new4 dropped8 reworded
Passage Bio added risks regarding accelerated FDA approvals, healthcare fraud laws, and privacy regulations. Budget Control Act Medicare cuts were extended through 2032.
Filed Mar 03, 2026 - FY2024 10-K risk factors65 risks
Passage Bio faces typical pre-revenue biotech risks dominated by its sole clinical candidate PBFT02 and novel gene therapy technology. Reliance on third-party manufacturers like Catalent and licensors like Penn creates significant operational dependencies. Intellectual property protection and raising additional capital are critical to future survival.
Filed Mar 04, 2025